World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
135
Citations
110634
World Ranking
2013
National Ranking
14

Overview

Tony Mok is affiliated with the Chinese University of Hong Kong in China, focusing primarily on medical research within pulmonary and respiratory medicine as well as oncology. Their work concentrates significantly on lung cancer treatments, mutations, and diagnostic methods, reflecting expertise in the intersection of medical science and cancer research.

The scientist's research output is substantial in the field of medicine, covering a total of 619 publications. Key subfields of study include pulmonary and respiratory medicine with 305 publications, oncology with 234 publications, cancer research with 49 publications, molecular biology with 27 publications, and radiology, nuclear medicine, and imaging with 20 publications.

Main topics of their work center on lung cancer treatments and mutations (352 publications), cancer immunotherapy and biomarkers (152 publications), lung cancer research studies (148 publications), lung cancer diagnosis and treatment (142 publications), colorectal cancer treatments and studies (96 publications), cancer genomics and diagnostics (92 publications), and gastric cancer management and outcomes (42 publications).

Frequent co-authors collaborating with Tony Mok include:

  • Yi-Long Wu (61 joint publications)
  • Solange Peters (47 joint publications)
  • Byoung Chul Cho (29 joint publications)
  • Enriqueta Felip (28 joint publications)
  • Filippo de Marinis (27 joint publications)

The scientist has contributed extensively to several prominent journals. Notable publication venues include the Journal of Clinical Oncology with 44 publications, Annals of Oncology with 43 publications, Journal of Thoracic Oncology with 34 publications, Lung Cancer with 19 publications, and Cancer Research with 16 publications.

Selected recent papers authored or co-authored by Tony Mok are:

  • "First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer," 2020, New England Journal of Medicine
  • "Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)," 2021, Journal of Clinical Oncology
  • "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study," 2020, Annals of Oncology
  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer," 2021, Journal of Thoracic Oncology

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

    Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Leora Horn;Aaron S. Mansfield;Aleksandra Szczęsna;Libor Havel

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

    T.S. Mok;Y.-L. Wu;M.-J. Ahn;M.C. Garassino

  • BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS)

    Masahiro Fukuoka;Yi-Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

Frequent Co-Authors

Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Anthony T.C. Chan
Anthony T.C. Chan Chinese University of Hong Kong
Philip J. Johnson
Philip J. Johnson University of Liverpool
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael Boyer
Michael Boyer University of Utah
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Lecia V. Sequist
Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring pathways beyond traditional medical degrees in the USA can open doors to diverse and rewarding healthcare careers. Many students and professionals are turning to online programs for flexibility, affordability, and faster completion times.

For those interested in mental health, accredited psychiatric np programs offer a direct route into advanced practice psychiatric nursing. These programs can often be completed quickly and entirely online, allowing for career advancement without prolonged time away from work.

If you’re drawn to leadership roles in hospitals or clinics, a health administration degree could be an excellent next step. There are numerous affordable online options, some even recognized for their quality and support.

For those considering a Master’s in Healthcare Administration, researching the cost of mha degree is key, as tuition varies considerably. Affordable programs make advancing your career more accessible.

Lastly, nurses seeking top clinical leadership roles may benefit from a 1 year dnp program online. These short and intensive doctorates prepare graduates for the highest levels of nursing practice.

Best Scientists Citing Tony Mok

Trending Scientists

Recently Published Articles